Lomitapide for the treatment of hypercholesterolemia.

about

Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.

P2860

Q47303571-49052B11-D2FC-42D8-98DB-32AC2D677574

P2860

Lomitapide for the treatment of hypercholesterolemia.

Item

http://www.wikidata.org/entity/Q50952184

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Lomitapide for the treatment of hypercholesterolemia.

@en

Lomitapide for the treatment of hypercholesterolemia.

@nl

type

Item

label

Lomitapide for the treatment of hypercholesterolemia.

@en

Lomitapide for the treatment of hypercholesterolemia.

@nl

prefLabel

Lomitapide for the treatment of hypercholesterolemia.

@en

Lomitapide for the treatment of hypercholesterolemia.

@nl

P1476

Lomitapide for the treatment of hypercholesterolemia.

@en

P2093

Amanda J Berberich

http://www.w3.org/2001/XMLSchema#string

P2860

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.

P304

1261-1268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1340941

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Hegele

P577

2017-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28598687

http://www.w3.org/2001/XMLSchema#string

P921

lomitapide

hypercholesterolemia

Lomitapide for the treatment of hypercholesterolemia.

about

P2860

P2860

Lomitapide for the treatment of hypercholesterolemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921